Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study

Table 2

Univariate analysis of factors associated with oral anticoagulant agent use among patients with nonvalvular atrial fibrillation.

	OACs not used		OACs used
		%		%
Sex					0.002
Male	202	23.8%	646	76.2%
Female	166	17.9%	763	82.1%
Age					<0.001
<50 years	83	50.9%	80	49.1%
50-75 years	193	17.6%	905	82.4%
>75 years	92	17.8%	424	82.2%
Hypertension					<0.001
No	142	33.6%	281	66.4%
Yes	226	16.7%	1128	83.3%
Diabetes mellitus					0.002
No	229	23.3%	752	76.7%
Yes	139	17.5%	657	82.5%
Current cigarette smoking					<0.001
No	282	18.4%	1250	81.6%
Yes	86	35.2%	158	64.8%
Type of atrial fibrillation					<0.001
Paroxysmal	229	34.0%	444	66.0%
Nonparoxysmal	139	12.6%	965	87.4%
Patient enrollment setting					<0.001
Outpatient	227	17.9%	1044	82.1%
Inpatient	141	27.9%	365	72.1%
Chronic kidney disease					0.440
No	330	20.5%	1282	79.5%
Yes	38	23.0%	127	77.0%
Stroke or systemic embolization					0.009
No	325	21.8%	1165	78.2%
Yes	43	15.0%	244	85.0%
Left ventricular ejection fraction					0.004
<40%	29	13.4%	187	86.6%
≥40%	319	21.9%	1137	78.1%
Heart failure					0.001
No	265	22.8%	895	77.2%
Yes	60	14.3%	360	85.7%
Ischemic heart disease
No	265	22.8%	895	77.2%
Yes	44	21.5%	161	78.5%
Body mass index					0.288
<25	79	21.6%	287	78.4%
≥25	240	19.1%	1018	80.9%
CHA2DS2-VASc score					<0.001
<2	126	49.4%	129	50.6%
≥2	242	15.9%	1280	84.1%
CHA2DS2-VASc					<0.001
<3	180	36.8%	309	63.2%
≥3	188	14.6%	1100	85.4%